Johnson & Johnson (J&J, NYSE: JNJ), a U.S.-based healthcare conglomerate, has released new clinical trial data for its BCMA-targeted chimeric antigen receptor (CAR) T cell therapy, Carvykti (ciltacabtagene autoleucel). The data reveals long-term overall survival (OS) for the therapy’s use as a second-line treatment for multiple myeloma (MM). The three-year follow-up from the Phase III CARTITUDE-4 study demonstrated that a single infusion of Carvykti extended OS in patients with relapsed or lenalidomide-refractory MM who had received at least one prior line of therapy, including a proteasome inhibitor (PI), by reducing the risk of death by 45% compared to the standard of care. The standard of care includes therapies such as pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd).
The latest trial data was featured as a late-breaking oral presentation at the 2024 International Myeloma Society (IMS) Annual Meeting. Johnson & Johnson highlighted that Carvykti is the first and only cell therapy to show improved OS compared to standard therapies for lenalidomide-refractory MM patients in the second-line setting. The U.S. FDA approved the expanded use of Carvykti for treating MM earlier this year. Originally developed by China-based Legend Biotech (NASDAQ: LEGN), Carvykti is co-developed by J&J on a global scale under a collaboration agreement.- Flcube.com
